
Regulatory12 Nov 2026, 11:28 am
Wanbury Ltd Gets Brazil FDA Approval for Metformin HCl API
AI Summary
Wanbury Limited has received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HCl EP grade. This marks the third consecutive approval from ANVISA for Wanbury's APIs, enabling their use in customer formulations. The company is focused on meeting customer demands, striving for quality excellence, and has initiated discussions with various customers to increase business volumes.
Key Highlights
- ANVISA (Brazil FDA) approved Metformin HCl EP grade API.
- This is the third consecutive API approval from ANVISA.
- Approval allows use of APIs in customer formulations.
- Company aims to increase business volumes with customers.
Price Impact
More from WANBURY